DelveInsight Releases Report on Heart Failure Drug Development
DelveInsight's new report "Heart Failure - Pipeline Insight, 2026" provides insights into over 70 companies and 75 drug development projects for heart failure treatment. The report covers both clinical and preclinical stages.
Business research firm DelveInsight has released a report titled "Heart Failure - Pipeline Insight, 2026." The report offers a comprehensive overview of the activities of over 70 companies and more than 75 drug development projects within the heart failure landscape.
It includes detailed profiles of pipeline drug candidates, encompassing their clinical and non-clinical stages. The report assesses therapies based on product type, developmental stage, route of administration, and molecule type. Additionally, it highlights inactive pipeline products in the field.
Heart failure is a syndrome resulting from structural and functional defects in the myocardium, impairing ventricular filling or blood ejection. It is considered a significant public health concern, with decades of advancements made in its treatment.
The report covers global regions and aims to provide an understanding of the current state and growth prospects of the heart failure pipeline. DelveInsight's previously published market research reports have focused on market dynamics, emerging trends, and future forecasts for heart failure treatments.